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primary percutaneous coronary intervention for ST-segment elevation myocardial
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Background/aim: This study investigated whether baseline serum level of C-reactive protein (CRP)/albumin ratio is associated with
infarct localization, number of vascular lesions, and in-hospital mortality in patients undergoing primary percutaneous coronary
intervention (PCI) for acute ST elevation myocardial infarction (STEMI).
Methods: The study population consisted of 116 patients diagnosed with STEMI. The CRP/albumin ratio at first admission, cardiac
troponin-I (cTnI), PCI results, and clinical outcomes were recorded.
Results: The mean CRP/albumin ratio, cTnI level, and mean number of vascular lesions were significantly higher in non-survivors than
in survivors (p = 0.006, p = 0.004, and p = 0.007, respectively). Multivariate logistic regression analysis demonstrated that the CRP/
albumin ratio and number of coronary artery lesions were independent predictors of mortality in STEMI patients. According to these
analyses, the presence of ≥ 2 vessel lesions was the most important predictor of mortality, with an odds ratio of 2.009 (95% confidence
interval: 1.191–3.387, p = 0.009).
Conclusion: This study demonstrates the potential utility of the CRP/albumin ratio for predicting the clinical outcome of patients with
STEMI. In addition, the presence of ≥ 2 vascular lesions contributed to a 2-fold increase in mortality rate in STEMI patients.
Key words: CRP/albumin ratio, infarction localization, prognosis, ST-elevation myocardial infarction, vascular lesion number

1. Introduction
Cardiovascular diseases, including coronary artery disease
(CAD), stroke, heart failure, peripheral artery disease,
carotid artery diseases, and aortoiliac diseases, are the most
important causes of mortality and morbidity worldwide
[1]. CAD occurs as a result of narrowing of the blood
vessels by atherosclerosis, which in turn causes a reduction
in the amount of oxygen delivered to the cardiac muscles,
thus leading to unstable angina, myocardial infarction
(MI), and heart failure [2].
The risk factors of CAD are well known and include
age, male sex, family history, smoking, hypertension,
diabetes, obesity, high total cholesterol level, high-density
lipoprotein cholesterol deficiency, excess of low-density
lipoprotein cholesterol, triglyceride level, a sedentary
lifestyle, and an increased waist circumference [2,3].
Atherosclerosis is an inflammatory disease that results
in CAD. Inflammation in the endothelium of the coronary
arteries is associated with increases in acute phase proteins

and cytokines. Focal and systemic inflammation play key
roles in the destabilization and rupture of atherosclerotic
plaque [4]. Consequently, inflammatory biomarkers are
being intensively studied for their ability to determine the
severity and prognosis of patients with CAD [5,6]. One
such biomarker is C-reactive protein (CRP), a prototype
marker of the inflammatory process that contributes to
CAD and is of interest as a biomarker of the disease [6,7].
Epidemiological studies have shown a relationship
between hypoalbuminemia and the development of CAD
[8,9]. In patients with CAD, hypoalbuminemia has also
been identified as a risk factor for the development of
new MI but there is no evidence of the prognostic value of
serum albumin levels in ST elevation myocardial infarction
(STEMI) patients [10,11]. Thus, a number of studies have
investigated the relationship between the serum CRP/
albumin ratio and inflammatory diseases such as sepsis,
cancer, acute pancreatitis, ulcerative colitis, hepatitis B,
and CAD [5–14].
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The ratio of serum levels of CRP to albumin has
been demonstrated to be a more accurate indicator
than albumin and CRP levels alone for determining the
prognosis of patients with various inflammatory diseases
such as sepsis, cancer, acute pancreatitis, ulcerative colitis,
and hepatitis B [12–20]. As atherosclerosis, and therefore
CAD, is an inflammatory process, the serum CRP level
may correlate with the severity of atherosclerosis and the
size of the atherosclerotic plaque [6,21].
In recent studies, CRP/albumin ratio, a novel
indicator of the inflammatory response, was shown to
be of moderate value as a marker of CAD and valuable
in predicting the development of stent restenosis and
disease prognosis following treatment with percutaneous
coronary intervention (PCI) [19,22,23]. However, the
relationship between the serum CRP/albumin ratio and
clinical outcome in patients undergoing PCI after acute
MI is not yet clear.
Therefore, the present study investigated whether the
baseline CRP/albumin ratio is associated with infarct
localization, number of vascular lesions, and in-hospital
mortality in patients undergoing PCI following a diagnosis
of acute STEMI.
2. Materials and methods
2.1. Study design and setting
This study was conducted in accordance with the 1989
Declaration of Helsinki and was approved by the Ethics
Committee of the Faculty of Medicine, University of
Health Sciences, İstanbul Research and Training Hospital
(ethical approval number 1453). The study population
in this prospective study consisted of 116 consecutively
enrolled adult patients admitted to the emergency
department (ED) of our tertiary care university hospital
between October 2018 and January 2019, where they
were diagnosed with STEMI. After the patient’s vital
functions had been monitored, written informed consent
was obtained directly from the patient or from his or her
authorized representative.
2.2. Selection of participants
Patients included in the study were those admitted to
the ED for chest pain or ischemia equivalent (especially
elderly, diabetic, and female patients, with symptoms
such as dyspnea, fatigue, and dizziness). All 116 patients
were subsequently diagnosed with ECG-confirmed acute
STEMI for which they underwent PCI and were then
admitted to the coronary intensive care unit (ICU). Age,
sex, smoking history, vital signs, electrocardiography
(ECG), symptoms, symptom duration, CRP/albumin
ratio at first admission, coronary angiography, and PCI
results (number of vascular lesions) were determined. The
clinical outcome (in-hospital mortality) was recorded in a
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pre-formatted case data form. Blood samples were taken
from the patients before PCI and used to measure CRP,
albumin, and cardiac troponin-I (cTnI; reference weight
0.02–0.06 ng/mL) levels. The relationships between the
CRP/albumin ratios as determined at first admission and
infarct localization, and number of vascular lesions were
analyzed. In addition, patients who were hospitalized
and then died in the hospital vs. those who survived and
were discharged were compared in terms of their CRP/
albumin ratio at first admission.
The inclusion criteria were patients with chest pain
and ischemia equivalent symptoms, age 18 years and over,
with an ECG-confirmed diagnosis of STEMI treated with
PCI, and oral or written consent obtained from the patient
or his/her guardian. Exclusion criteria were individuals
under 18 years of age, patients with cardiac arrest before
PCI, patients with non-STEMI; patients/guardians who
did not provide oral or written consent; patients who
within the last 1 week took medications that may affect
the CRP level (antiinflammatory, antibiotic, statins, etc.);
patients with accompanying systemic infection.
2.3. Statistical analysis
The required sample size was calculated by power analysis
before data collection. It was estimated that at least 111
patients would be required to detect significant differences
among the numerical variables with a power of 95% and
an alpha error of 5%. All analyses were conducted using
SPSS statistical software (version 15.0 for Windows; SPSS,
IBM Corp., Armonk, NY). Numerical data (e.g., CRP/
albumin, neutrophil/lymphocyte, cTnI level, number of
vascular lesions, and symptom duration) are expressed
as means ± standard deviations (SDs) and minimum
and maximum (min–max) values, and categorical
variables (sex and age) are expressed as numbers (n) and
percentages (%).
The distribution of the included patients’ data
was examined for normality. Therefore, intergroup
comparisons (survivors vs. nonsurvivors) were conducted
using the independent-samples t test and chi-square test
for normally distributed data and Mann–Whitney U-test
for nonnormally distributed data. Intragroup comparisons
(STEMI groups) were made using the Kruskal–Wallis
test. To normalize the distributions, extreme values were
ignored, but that did not eliminate the distortions of the
variables. Spearman’s rank correlation test was used to
evaluate the correlation between the CRP/albumin ratio
and the number of vascular lesions. Multivariate logistic
regression analysis was performed to identify significant
predictors of mortality, including serum levels of CRP/
albumin, hs-cTnI, and number of vascular lesions.
Confidence intervals were given at the 95% level (95% CI)
and p < 0.05 was taken to indicate statistical significance.
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3. Results
The study population consisted of 100 male (86.2%) and
16 female (13.8%) patients with STEMI. Their mean
age was 56.47 ± 11.42 years (range: 28–86 years). There
were no statistically significant differences between
survivors and non-survivors in terms of age, sex, and
symptom duration parameters (p = 0.125, p = 0.700, and
p = 0.569, respectively; Table 1). Likewise, there were
no statistically significant differences between survivors
and non-survivors in terms of the mean albumin levels
(4.40 ± 3.01 vs. 3.86 ± 0.44, respectively, p = 0.457) or CRP
(12.75 ± 18.31 vs. 25.34 ± 33.66, respectively, p = 0.139).
However, the mean CRP/albumin ratio, cTnI level, and
mean number of vascular lesions were significantly higher
in non-survivors than in survivors (p = 0.006, p = 0.004,
and p = 0.007, respectively; Table 1 and Figures 1–3).
In multivariate logistic regression analyses, the CRP/
albumin ratio and number of coronary artery lesions
remained independent predictors of mortality in patients
diagnosed with STEMI. The number of vascular lesions
was the most important predictor of mortality, with an
odds ratio of 2.009 (95% CI: 1.191–3.387, p = 0.009; Table
2). In fact, the presence of ≥ 2 vascular lesions increased
the risk of mortality in STEMI patients by 2-fold.
The patients were also classified according to the
ECG-based MI localization as follows: group I: inferior
STEMI, group II: anterior STEMI, and group III: other
(lateral, right, posterior, etc.) STEMI. While there was no
statistically significant difference between the groups in
terms of mean CRP/albumin ratio (p = 0.119 and Table 2),
mean serum cTnI levels were significantly higher in group
II (anterior STEMI) than in group I (inferior STEMI)

patients (4.56 ± 10.56 and 0.63 ± 3.03, respectively;
p = 0.039; Table 3). The difference in the serum cTnI level
between the other groups was not statistically significant
(p > 0.05; Table 3).
The patients were also grouped according to the
number of vascular lesions following PCI. Group 1
consisted of those with 0 or 1 vascular lesions, and group
2 consisted of those with ≥ 2 lesions. The two groups did
not significantly differ in their symptom duration, CRP/
albumin ratio, and cTnI levels (p = 0.305, p = 0.614, and
p = 0.464, respectively; Table 4). By contrast, the mean age
of group 2 patients was significantly higher than that of
group 1 patients (p = 0.031; Table 4). Finally, there was no
significant relationship between the CRP/albumin ratio
and the number of vascular lesions (Spearman’s correlation
coefficient, ρ = 0.121, p = 0.199).
4. Discussion
This is the first clinical study to evaluate the relationships
between serum CRP/albumin levels and infarct
localization, number of vascular lesions, and in-hospital
mortality in the early period in adult patients diagnosed in
the ED with acute STEMI and treated with PCI.
Acute coronary syndrome is the most important
potentially fatal disease and its occurrence does not differ
between males and females [24]. Complications and death
due to STEMI have decreased significantly in recent years,
due to current and evidence-based treatment modalities
[25]. Atherosclerosis-induced CAD is an inflammatory
process, and the serum CRP level, as a marker of
inflammation, correlates with disease severity and plaque
width [19]. Recent studies have shown that the CRP/

Table 1. Comparison of demographic, clinical, laboratory and coronary angiographic characteristics in surviving and nonsurviving patients.
Survivors
(n = 98)

Characteristic

Age
Sex (n, %)

Non-survivors
(n = 18)

Mean ± SD

Min–max

Mean ± SD

Min–max

p-value*

55.78 ± 10.95

28–86

60.28 ± 13.42

40–85

0.125

Male

85 (86.7%)

Female

13 (13.3%)

15 (83.3%)

0.700

3 (16.7%)

CRP/albumin (mg/L/g/dL)

3.18 ± 4.99

0.11–25.88

6.41 ± 8.01

0.21–30.82

0.006

cTnI (ng/mL)
Number of vascular lesions
Symptom duration (h)

3.26 ± 10.11
1.61 ± 0.85
8.67 ± 15.61

0.01–68.30
0–4
0.50–72

4.94 ± 11.02
2.39 ± 1.19
16.50 ± 23.40

0.01–46.82
1–4
0–72

0.004
0.007
0.569

Note: Data are expressed as numbers, percentages, mean ± standard deviation (SD), and minimum and maximum (Min–
max) values. *Intergroup comparisons (survivors vs. non-survivors) were made using an independent sample t-test as well as
chi-squared and Mann–Whitney U tests as appropriate.
Abbreviations: CRP, C-reactive protein; cTnI, cardiac troponin-I.
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Figure 1. Distribution of cardiac troponin-I levels in survivors and non-survivors.

Figure 2. Distribution of the number of vascular lesions in survivors and non-survivors.

albumin ratio is related to the clinical outcome in various
diseases, and may be a prognostic indicator of CAD [12–
15,19,20].
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The use of the CRP level to predict coronary events has
been examined [6]. Wada et al. [19] evaluated 2164 patients
diagnosed with CAD who underwent PCI. Based on an
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Figure 3. Distribution of the C-reactive protein/albumin ratio in survivors and non-survivors.
Table 2. Independent predictors of mortality in patients with STEMI identified in multivariate logistic
regression analysis.
Predictor

Beta

OR (95% CI)

SD

p-value

CRP/albumin (mg/L/g/dL)

0.166

1.249 (0.966–2.139)

0.153

0.038

cTnI (ng/mL)

0.008

1.008 (0.953–1.066)

0.029

0.786

Number of vasculer lesions

0.697

2.009 (1.191–3.387)

0.266

0.009

Abbreviations: STEMI, ST elevation myocardial infarction; CRP, C-reactive protein; cTnI, cardiac
troponin-I; Beta, standardized regression coefficient; OR, odds ratio; CI, confidence interval; SD,
standard deviation; P, statistical significance.

average follow-up of 7.5 years, low serum albumin levels
together with high CRP levels were shown to be associated
with long-term adverse cardiac events (all-cause death and
nonfatal myocardial infarction). In addition, low serum
albumin and high CRP levels had a synergistic effect on
the risk of developing long-term adverse cardiac events in
patients undergoing PCI.
In the present study, mean CRP/albumin levels were
significantly higher in patients who eventually died than
in those who survived to hospital discharge. This result is
in accordance with the study of Wada et al. In addition,
serum cTnI levels and the number of vascular lesions were
significantly higher in non-survivors. In contrast, there
were no significant differences in the age, sex distribution,
and symptom duration of survivors vs. non-survivors.
In our study of STEMI patients who underwent PCI,

we investigated the predictive value of the serum CRP/
albumin ratio as measured at first admission, which
increased the utility of our findings compared to those
of Wada et al. Thus, the early determination of cTnI
levels and serum CRP/albumin levels may serve as a new
biomarker to predict a poor clinical outcome in patients
with STEMI. In our study, multivariate logistic regression
analysis showed that ≥ 2 coronary artery lesions doubled
the risk of death, and the CRP/albumin ratio was another
independent predictor of mortality in patients diagnosed
with STEMI.
A previous study showed that CRP is not an appropriate
diagnostic marker of acute MI in patients presenting to
the ED with chest pain. However, serum CRP values more
than one-third higher than the upper limit are associated
with increased in-hospital adverse cardiac events in these
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Table 3. Comparison of the serum CRP/albumin ratio and cTnI level among STEMI patients grouped according to
the ECG-based MI localization.
Group I
(n = 38)

Group II
(n = 57)

Group III
(n = 19)

Mean ± SD

Mean ± SD

Mean ± SD

CRP/albumin (mg/L/g/dL)

3.16 ± 5.12

3.63 ± 5.47

cTnI (ng/mL)

0.63 ± 3.03 *

4.56 ± 10.56 **

Parameter

a

p-value

5.14 ± 7.31
b

0.539

6.08 ± 16.55

c***

0.039

Group 1 vs. group 2: *p = 0.032
Group 2 vs. group 3: **p > 0.976
c
Group 3 vs. group 1: ***p > 0.437
Note: Data are reported as the number and mean ± standard deviation. Intragroup comparisons (STEMI groups)
were performed by the Kruskal–Wallis test. Group I, inferior STEMI; group II, anterior STEMI; group III, other
(lateral, right, posterior, etc.).
Abbreviations: ECG, electrocardiography; MI, myocardial infarction; STEMI, ST elevation myocardial infarction;
CRP, C-reactive protein; cTnI, cardiac troponin-I.
a

b

Table 4. Comparison of patient age, symptom duration, serum CRP/albumin ratio, and serum cTnI levels among STEMI
patients grouped according to the number of vascular lesions.
Parameter

Group 1
(n = 61)

Group 2
(n = 55)

Mean ± SD

Min–max

Mean ± SD

Min–max

p-value*

Age

54.31 ± 11.33

29–86

58.87 ± 11.14

28–79

0.031

CRP/albumin (mg/L/g/dL)

2.97 ± 4.66

0.13–30.82

4.49 ± 6.55

0.11–25.88

0.614

cTnI (ng/L)
Symptom duration (h)

4.33 ± 12.47
8.52 ± 15.46

0.01–68.30
0.00–72.00

2.61 ± 6.96
11.04 ± 18.43

0.01–40.35
0.50–72.00

0.464
0.305

Note: Data are reported as number, mean ± standard deviation (SD), minimum and maximum min–max). *An independent
sample t-test was used to compare the sex distribution of the two groups, and the Mann–Whitney U test to compare symptom
duration, serum CRP/albumin ratio, and serum hs-cTnI levels between groups.
Group 1, 0–1 vascular lesions; group 2, ≥ 2 vascular lesions.
Abbreviations: ECG, electrocardiography; MI, myocardial infarction; STEMI, ST elevation myocardial infarction; CRP,
C-reactive protein; cTnI level, cardiac troponin-I.

patients [26]. Similarly, in the present study, a comparison
of survivors and non-survivors (in-hospital mortality)
showed that a high CRP/albumin ratio, measured at
first admission associated with in-hospital mortality in
the short term. A recent study showed that decreased
albumin level is an independent predictor of in-hospital
mortality in patients with ACS [27]. Another recent study
demonstrated that an increased CRP/albumin ratio can
predict coronary microvascular dysfunction better than
CRP or albumin alone in patients with celiac disease [28].
Consistent with those findings, we found that the mean
CRP/albumin ratio was significantly higher in survivors
than non-survivors, despite no significant differences
in the mean albumin levels or CRP alone between the
two groups. In addition, the increased CRP/albumin
ratio remained an independent predictor of in-hospital
mortality in patients diagnosed with STEMI.
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It has been implicated that the total quantity of cardiac
enzyme released into plasma correlates with the infarct
size [29]. Previous studies reported that patients with the
maximum cTnI level more likely had anterior wall MI with
consequent large infarct size [30,31]. In the present study,
when STEMI patients were examined according to MI
localization (group I: inferior MI, group II: anterior MI,
and group III: lateral, right, posterior, etc.), there was no
statistically significant difference between the groups in
terms of their mean serum CRP/albumin ratio. However,
the mean serum cTnI level was significantly higher in
group II (anterior MI) than in group I (inferior MI)
patients.
Increased age is one of the most important risk factors
of CAD, increasing its incidence and prevalence [32,33]. In
the present study, among patients evaluated according to
the number of vascular lesions after PCI (group 1 with 0–1
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and group 2 with ≥ 2 vascular lesions), patients in group
2 were significantly older than those in group 1, whereas
there were no statistically significant differences between
the groups in terms of symptom duration, serum CRP/
albumin ratio, or cTnI level. However, we did find that the
number of vascular lesions increased with age and that the
presence of ≥ 2 vascular lesions was the most important
predictor of mortality in patients with STEMI. These
findings imply that advanced age is the most important
risk factor for CAD.
This study had some limitations, the most important of
which were the small sample size and single-center design.
In addition, we were able to obtain data containing only
one-time point measurement for cTnI and inflammation
parameter, such as CRP/albumin ratio, for each patient.
Blood samples were taken upon admission of the subjects
to the ED. These issues should be addressed in future
studies involving patients with STEMI.
In conclusion, this study demonstrates the value of the
CRP/albumin ratio, cTnI level, and number of affected
coronary vessels in predicting the short-term clinical
outcome of STEMI patients undergoing primary PCI.
We also revealed that the number of vascular lesions in
these patients increased with age, and in multivariate
logistic regression analyses age was an independent

predictor of a 2-fold increase in mortality rate in patients
with STEMI. However, the CRP/albumin ratio was not
useful in determining infarct localization and width.
Rather, we recommend the use of the CRP/albumin ratio
in conjunction with other prognostic scoring systems
or laboratory parameters to predict the short-term
prognosis of patients with STEMI, as it is an inexpensive,
reproducible, systemic biomarker of inflammation and
therefore of CAD. Further randomized and controlled
studies with larger sample sizes are needed to confirm
these findings.
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